Tags
Swedish Multiple Sclerosis Blog Blog

'neuroscience' Swedish Multiple Sclerosis Blog posts

New medication for MS, Tecfidera (BG-12), Approved by FDA

On March 27, the U.S. Food and Drug Administration approved the newest treatment in the increasing number of disease modifying therapies (DMTs) available to treat multiple sclerosis. Tecfidera (BG-12) is an oral capsule to treat adults with relapsing forms of MS. Research participants at the MS Center at Swedish participated in clinical trials for Tecfidera.

 

The trials reported that people taking Tecfidera had fewer relapses and less frequent worsening of disability compared to people taking a placebo. There were also fewer and less-severe side effects with Tecfidera than other treatments.

 

The studies found that ...

Stride with Swedish April 14 for Multiple Sclerosis

Every hour, someone is diagnosed with multiple sclerosis (MS). And every day, people from around the Pacific Northwest and United States visit the MS Center at Swedish to learn how to live well with the disease.

Multiple sclerosis is a disease of the nervous system that affects the brain, eyes and spinal cord that takes a unique course in every patient. We’re with people on their journey, whether they are newly diagnosed or have been living with MS for decades. Patients and families share their lives with our treatment team and, in turn, we put our passion into helping them achieve their highest wellbeing.

Participating in Walk MS one way we show our commitment to caring for the MS community.

Swedish Presents Research at 2013 AAN Annual Meeting

Neurologists and neuroscience professionals this week from around the world gathered at the American Academy of Neurology (AAN) 65th Annual Meeting in San Diego. The Multiple Sclerosis Center at Swedish Neuroscience Institute was pleased to co-author a few research trials presented at the meeting:

 

Teriflunomide and pregnancy

Dr. Lily Jung-Henson speaking at the AAN 65th Annual MeetingDr. Lily Jung-Henson, neurologist and Chief of Staff at Swedish Issaquah, spoke on behalf of a team of researchers about teriflunomide and a report on the safety of women who became pregnant on the medication. Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) recently approved in the United States to treat relapsing multiple sclerosis. Clinical trials for teriflunomide took place among the many research studies for new treatments Swedish Neuroscience Institute offers patients with multiple sclerosis. (Read the full abstract here.)

Subset of a trial looking at endurance effects of Dalfampridine (AMPYRA®)

Dr. Angeli Mayadev, physical medicine and rehabilitation specialist at the MS Center, participated in this study of a medication to improve walking speed in people with MS. Dalfampridine -ER 10 mg twice daily significantly improved 6-minute walking distance compared to placebo. Dalfampridine 5 mg twice daily did not improve distance compared to placebo. Researchers also found that ....

MS Research Update: Pulse therapy for breakthrough multiple sclerosis

A small pilot study from the University of Southern California suggests a pulse adrenocorticotropic hormone (ACTH) therapy could be effective in patients with breakthrough multiple sclerosis attacks while on beta-interferon. “Breakthrough” attacks that occur after starting a disease modifying therapy (DMT).

 

The study compared the safety and benefits of monthly pulse ACTH to monthly methylprednisone (MP) pulse in patients on beta-interferon. Over 15 months, researchers found that those treated with ACTH had fewer relapses and fewer psychiatric side effects. ACTH gel is currently used to treat MS relapses, but researchers note it may be able to alter the body’s immune responses beyond producing steroids.

 

As I discussed with the Medscape reporter, Megan Brooks, last week, the results of this study are ....

Seahawks’ Blitz and Dr. Bowen Demystify MS

Dr. James Bowen appeared today with Ryan Asdourian, “the man behind the bird” and Seahawks’ mascot Blitz, on the Seattle talk show New Day Northwest to shed some light on common misconceptions about multiple sclerosis (MS).

 

Host Margaret Larson asked Dr. Bowen about myths about MS as part of the program to promote this year’s Walk MS events in Seattle. Ryan Asdourian is proof of the full life many people lead with MS, rallying fans at Seahawks games and raising MS awareness as an active advocate for the National Multiple Sclerosis Society.

 

You can check out the video from KING5 TV’s website below. Find out more about how to join or donate to the Swedish S’myelin Strider’s Walk MS team at www.swedish.org/MS.

Finding Art in the Multiple Sclerosis Experience Third-Annual MS Art Show Set for June 16

SEATTLE, June 11, 2012 – Multiple Sclerosis (MS) sucks, as the painting says, but it also inspires art. The MS Center at Swedish is set to unveil its third-annual Art Show. Those touched by MS and living in the Pacific Northwest have been invited to submit their work. No visual media is off limits; all people living with and affected by MS from the Northwest region are accepted. The show's goal is to enhance wellness and quality of life for individuals affected by the disease.

Results 36-41 of 41